Bear;
"Entresto (sacubitril and valsartan) is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction."
Can a comparison be made between Entresto and Apabetalone for patients suffering from congestive heart failure?
https://www.everydayhealth.com/heart-failure/living-with/congestive-heart-failure-life-expectancy/
Koo
